header logo image

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic…

September 29th, 2022 1:50 am

WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver phenotypes

Read the original here:
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic...

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick